| Literature DB >> 34070025 |
Marco V Marino1,2, Adrian Kah Heng Chiow3, Antonello Mirabella1, Gianpaolo Vaccarella1, Andrzej L Komorowski4.
Abstract
BACKGROUND: Different techniques of pancreatic anastomosis have been described, with inconclusive results in terms of pancreatic fistula reduction. Studies comparing robotic pancreaticogastrostomy (PG) and pancreaticojejunostomy (PJ) are scarcely reported.Entities:
Keywords: pancreatic fistula; pancreato-gastrostomy; robotic pancreatic surgery
Year: 2021 PMID: 34070025 PMCID: PMC8158101 DOI: 10.3390/jcm10102181
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Exclusion criteria from the study.
| Unsuitability for pneumoperitoneum |
| ASA score > III |
| Body mass index (BMI) < 35 kg/m2 |
| Borderline or Locally advanced tumours |
| Intraperitoneal or extraperitoneal metastases |
| Tumor size > 5 cm |
| Patients who underwent total pancreatectomy |
| Patients requiring concomitant organ or vascular resection |
| Conversion to open |
Abbreviation: ASA, American Society of Anaesthesiologists.
Demographic, pre-operative characteristics and risk factors variables for post-operative pancreatic fistula (POPF) of patient undergoing robotic pancreatojejunostomy (PJ) and pancreatogastrostomy (PG).
| Variables | PJ ( | PG ( | Overall ( | |
|---|---|---|---|---|
| Age, years, median (IQR) | 63.2 (55.6–71.4) | 61.9 (53.8–68.5) | 62.9 (54.1–71.1) | 0.688 |
| Sex, | ||||
|
Male | 27 (67.5%) | 13 (65%) | 40 (66.7%) | 0.627 |
|
Female | 13 (32.5%) | 7 (35%) | 20 (33.3%) | 0.799 |
| BMI, Kg/m2, mean (±SD) | 25.1 ± 3.4 | 24.8 ± 2.8 | 25 ± 3.2 | 0.824 |
| ASA score, mean (±SD) | 2.5 ± 0.06 | 2.2 ± 0.04 | 2.4 ± 0.7 | 0.856 |
| Pathology | ||||
|
Malignant | 30 (75%) | 15 (75%) | 45 (75%) | 1 |
|
PDAC | 21 | 8 | 29 | |
|
IPMN Cancer | 3 | 2 | 5 | |
|
Ampullary Carcinoma | 2 | 2 | 4 | |
|
Cholangiocarcinoma | 2 | 2 | 4 | |
|
Duodenal Carcinoma | 1 | 1 | 2 | |
|
NEC | 1 | / | 1 | |
|
Benign | 10 (25%) | 5 (25%) | 15 (25%) | 1 |
|
IPMN | 4 | 2 | 6 | |
|
Serous cystic Neoplasm | 3 | 1 | 4 | |
|
MCN | 2 | 1 | 3 | |
|
Chronic Pancreatitis | 1 | 1 | 2 | |
| Tumor size, cm, mean (±SD) | 2.86 ± 1.7 | 2.55 ± 1.4 | 2.8 ± 1.6 | 0.822 |
| Neoadjuvant CHT, | 6 (15%) | 2 (10%) | 8 (13.3%) | 0.479 |
| Pancreatic texture, | 1 | |||
|
Soft | 16 (40%) | 8 (40%) | 24 (40%) | |
|
Hard | 24 (60%) | 12 (60%) | 36 (60%) | |
| Wirsung duct diameter, median ± SD | 3.4 ± 2.4 | 2.9 ± 2.5 | 3.2 ± 2.4 | 0.627 |
|
≥3 mm, | 31 (77.5%) | 14 (70%) | 45 (75%) | 0.669 |
|
<3 mm, | 9 (22.5%) | 6 (30%) | 15 (25%) | 0.611 |
| ISGPS classification | ||||
|
A | 19 (47.5%) | 9 (45%) | 28 (46.7%) | 0.821 |
|
B | 5 (12.5%) | 3 (15%) | 8 (13.3%) | 0.793 |
|
C | 12 (30%) | 5 (25%) | 17 (28.3%) | 0.645 |
|
D | 4 (10%) | 3 (15%) | 7 (11.7%) | 0.612 |
| Mean CRS-POPF ± SD | 4.6 ± 2.2 | 5.1 ± 1.8 | 4.7 ± 2.1 | 0.433 |
| Histopathology, | ||||
|
Ampullary/Duodenal/Cystic | 8 (20%) | 5 (25%) | 13 (21.7%) | 0.523 |
|
PDAC/IPMN/others | 32 (80%) | 15 (75%) | 47 (78.3%) | |
| Estimated blood loss | ||||
|
≥500 mL | 8 (20%) | 4 (20%) | 12 (20%) | 1 |
|
<500 mL | 32 (80%) | 16 (80%) | 48 (80%) | |
| Categories of POPF risk, | 0.788 | |||
|
Negligible | 6 (15%) | 2 (10%) | 8 (13.3%) | |
|
Low | 16 (40%) | 6 (30%) | 22 (%) | |
|
Intermediate | 14 (35%) | 9 (45%) | 23 (35%) | |
|
High | 4 (10%) | 3 (15%) | 7 (11.7%) |
BMI: Body Mass Index, ASA: American Society of Anesthesiologists, PDAC: Pancreatic Ductal Adenocarcinoma, IPMN: Intraductal Papillary Mucinous Neoplasm, NET: Neuroendocrine Cancer, MCN: Mucinous Cystic Neoplasm, CHT: Chemotherapy, CRS: Clinical risk score, POPF: Post-operative pancreatic fistula.
Postoperative outcomes of patients who underwent PJ vs. PG reconstruction.
| Variables | PJ ( | PG ( | Overall ( | |
|---|---|---|---|---|
| Operative time, min, median ± SD | 375 ± 102 | 315 ± 110 | 355 ± 103 | 0.345 |
| Time of the anastomoses, min, median ± SD | 32 ± 11 | 25 ± 14 | 30.2 ± 12 | 0.002 |
| Estimated blood loss, ml, median (IQR) | 270 (180–600) | 295 (200–700) | 275 (180–600) | 0.442 |
| Intraoperative blood transfusion, | 3 (7.5%) | 1 (5%) | 4 (6.7%) | 0.766 |
| Post-operative complications, | 19 (47.5%) | 9 (45%) | 28 (46.6%) | 0.635 |
|
Grade < III | −11 (27.5%) | −6 (30%) | −17 (28.3%) | 0.826 |
|
Grade ≥ III | −8 (20%) | −3 (15%) | −11 (18.3%) | 0.542 |
|
Biochemical leak | 5 (12.5%) | 3 (15%) | 8 (13.3%) | 0.524 |
| CR-POPF | 5 (12.5%) | 2 (10%) | 7 (11.7%) | 0.827 |
|
Grade B | −3 (7.5%) | −1 (5%) | −4 (6.7%) | 0.789 |
|
Grade C | −2 (5%) | −1 (5%) | −3 (5%) | 0.977 |
| Delayed gastric emptying, | 2 (5%) | 1 (5%) | 3 (5%) | 0.928 |
| Grade C Postoperative hemorrhage, | 1 (2.5%) | 2 (10%) | 3 (5%) | 0.338 |
| Pancreatitis, | 1 (2.5%) | / | 1 (1.4%) | 0.782 |
| Bile leakage, | 1 (2.5%) | 1 (5%) | 2 (3.3%) | 0.654 |
| Ascites, | 1 (2.5%) | / | 1 (1.4%) | 0.782 |
| Intra-abdominal collection, | 3 (7.5%) | / | 3 (4.3%) | 0.002 |
| Length of hospital stays, days, median ± SD | 14 ± 4 | 11 ± 6 | 15.8 ± 5 | 0.223 |
| Readmission, | 4 (10%) | 1 (5%) | 5 (8.3%) | 0.524 |
| Reoperation, | 2 (5%) | 1 (5%) | 3 (5%) | 0.928 |
| Mortality 90-days, | 2 (5%) | 1 (5%) | 3 (5%) | 0.928 |
CR-POPF: Clinically Relevant Postoperative pancreatic fistula.
Comparison of postoperative results of PJ and PG cohorts matched for the four variables (histopathology, pancreatic texture, pancreatic duct diameter, intraoperative blood loss) of the clinical risk score for post-operative pancreatic fistula (POPF).
| Variables | PJ ( | PG ( | |
|---|---|---|---|
| Histopathology, | |||
| - PDAC/IPMN | 14 (70%) | 15 (75%) | 0.855 |
| - Ampullary, Duodenal, Cystic | 6 (30%) | 5 (25%) | 0.793 |
| Pancreatic texture, | |||
| - Soft | 13 (65%) | 13 (65%) | 1 |
| - Hard | 7 (35%) | 7 (35%) | 1 |
| Pancreatic duct diameter, mm, | |||
| - ≥3 | 13 (65%) | 14 (70%) | 0.643 |
| - <3 | 7 (35%) | 6 (30%) | 0.635 |
| ISGPS Classification | |||
| - A | 9 (45%) | 9 (45%) | 1 |
| - B | 3 (15%) | 3 (15%) | 1 |
| - C | 5 (25%) | 5 (25%) | 1 |
| - D | 3 (15%) | 3 (15%) | 1 |
| Intraoperative blood loss, mL, | |||
| - ≥500 | 5 (25%) | 4 (20%) | 0.617 |
| - <500 | 15 (75%) | 16 (80%) | 0.539 |
| Median Operative time, min (IQR) | 330 (270.2–395.8) | 315 (265–382) | 0.75 |
| Anastomotic time, min (IQR) | 46 (28–52) | 25 (18–40) | 0.002 |
| Morbidity rate, | 11 (55%) | 9 (45%) | 0.721 |
| - Minor | 5 (25%) | 6 (30%) | 0.586 |
| - Major | 6 (30%) | 3 (15%) | 0.324 |
| Biochemical Leak, | 4 (20%) | 3 (15%) | 0.721 |
| CR–POPF, | 3 (15%) | 2 (10%) | 0.478 |
| Delayed gastric emptying, | 1 (5%) | 1 (5%) | 1 |
| Post-pancreatectomy hemorrhage, | / | 2 (10%) | 0.003 |
| Intra-abdominal collection, | 3 (15%) | / | 0.002 |
| Reoperation, | 2 (10%) | 1 (5%) | 0.474 |
| Median length of hospital stays, days (IQR) | 14.2 (12.4–22) | 11.5 (9.5–19) | 0.165 |
Risks factors for POPF.
| Variables | CR-POPF | No-POPF | Univariate | Odds | 95% CI |
|---|---|---|---|---|---|
| Age | |||||
|
≥65 years | 4 | 27 | 0.76 | ||
|
<65 years | 3 | 26 | |||
| Sex | |||||
|
Male | 4 | 36 | 0.57 | ||
|
Female | 3 | 17 | |||
| BMI | |||||
|
≥25 Kg/m2 | 5 | 14 | <0.05 | 6.96 | (1.2–40.1) |
|
<25 Kg/m2 | 2 | 39 | |||
| Diabetes | |||||
|
YES | 1 | 10 | 0.77 | ||
|
NO | 6 | 43 | |||
| ASA score | |||||
|
≥3 | 3 | 29 | 0.55 | ||
|
<3 | 4 | 24 | |||
| Pancreatic duct diameter | |||||
|
≥3 mm | 2 | 43 | |||
|
<3 mm | 5 | 10 | <0.05 | 10.7 | (1.8–63.6) |
| Underlying pathology | |||||
| PDAC/IPMN/etc. | 4 | 43 | 0.16 | ||
| Ampullary/Cystic/Duodenal | 3 | 10 | |||
| Tumor size | |||||
|
≥2.5 cm | 2 | 21 | 0.59 | ||
|
<2.5 cm | 5 | 33 | |||
| Texture of the pancreas | |||||
|
Soft | 6 | 18 | <0.05 | 11.66 | (1.3–104.4) |
|
Hard | 1 | 35 | - | ||
| Operative time | |||||
|
≥355 min | 4 | 34 | 0.71 | ||
|
<355 min | 3 | 19 | |||
| Blood loss | |||||
|
≥500 mL | 5 | 7 | <0.05 | 10.95 | (2.1–56.3) |
|
<500 mL | 2 | 46 | - | ||
| Reconstruction type | |||||
|
PJ | 5 | 35 | 0.77 | ||
|
PG | 2 | 18 |
BMI: Body Mass Index, ASA: American Society of Anesthesiologist, PDAC: Pancreatic ductal adenocarcinoma, IPMN: Intraductal Papillary Mucinous Neoplasm, PJ: Pancreatojejunostomy, PG: Pancreatogastrostomy.
Figure 1Rate of the clinically relevant postoperative pancreatic fistula (CR-POPF) in a subgroup analysis.